Immunotherapy holds the potential to induce durable responses, but only a minority of
patients currently respond. The etiologies of primary and secondary resistance to …

Cancer immunotherapy is gaining momentum in the clinic. The current challenge is to
understand why a proportion of cancer patients do not respond to cancer immunotherapy …

Cancer is a worldwide medical problem with significant repercussions on individual patients
and societies as a whole. In order to alter the outcomes of this deadly disease the treatment …

For tumor antigen-specific T cells to effectively control the growth of cancer cells in vivo, they
must gain access to, and function within, the tumor microenvironment. While tumor antigen …

Resistance to anticancer therapies includes primary resistance, usually related to lack of
target dependency or presence of additional targets, and secondary resistance, mostly …

There is much promise in the use of immunotherapy for the treatment of cancer. Approaches
such as those using antibodies or adoptive cell transfer can mediate complete tumor …

During the past two decades, the paradigm for cancer treatment has evolved from relatively
nonspecific cytotoxic agents to selective, mechanism-based therapeutics. Cancer …

Advances in immunotherapy have achieved remarkable clinical outcomes in tumors with low
curability, but their effects are limited, and increasing evidence has implicated tumoral and …

With the rapid clinical development of immune checkpoint inhibitors (ICIs), the standard of
care in cancer management has evolved rapidly. However, immunotherapy is not currently …

Recent exciting progress in cancer immunotherapy has ushered in a new era of cancer
treatment. Immunotherapy can elicit unprecedented durable responses in advanced cancer …